Abstract
Multisample analysis from all temporally or spatially distinct samples obtained for each patient. A, Conservation of chromothripsis and corresponding amplifications across all samples with available data from individual patients. ^ indicates lower purity samples compared with the other sample from same patient (Supplementary Table S5); CN values in such samples may be falsely low. * indicates chromothripsis detected by WGS only, but not detected by tNGS. N/A, not available: sample without NGS or IHC. Sample numbering is chronologic (Supplementary Table S3). B, Multisample analysis showing RB1 and TP53 genomic alterations and expression of pRb, p53, and p16 by IHC, illustrating a subset of patients with acquired or subclonal RB1 alterations/loss (details in Supplementary Table S1) and a subset with unusual patterns of p16 expression (see “Results”). C, Illustration of a case with acquired RB1 mutations and loss of expression in metastatic samples. pRb-positive cells admixed with negative tumor cells in panels on the right are benign lymphocytes and stromal cells, serving as internal controls. Scale bars are 100 μm, except for the left bottom, which is 1 mm. D, RNA-seq for CDKN2A, encoding p16. Arrows indicate cases with chromothripsis of chromosome 12 and ecDNA amplification of CDK4. TPM, transcripts per million. (C, created in part with BioRender.com.)